Multiplex Biomarker Imaging Market: By Product Type (Instrument, Reagents and Kits, Software), By Imaging Technique (Tissue Microarray (TMA), Toponome Imaging System (TIS), Fluorescent In The Situ Hybridization (FISH), Immunofluorescence Assay (IF), Immunohistochemistry Assay (IHC)), By Application (Oncology, Immunology, Drug Safety, Drug Discovery), By End-User (Biotechnology and Pharmaceutical Companies, Academic Research Institutes, Contract Research Organizations), and Geography   

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Multiplex Biomarker Imaging Market size was estimated at USD 561.2 Mn in 2021, growing at a CAGR of 12.1% during the forecast period 2022-2028. Increase in the adoption of the multiplex biomarker in immunology and oncology research, growing R&D investments by pharmaceutical and biotechnology companies, increase in demand for personalized medicine, and innovation of newer technologies in biomarker imaging are anticipated to fuel the multiplex biomarker imaging market size over the forecast period. Moreover, increase in preference for companion diagnostics and advantages of multiplex biomarker imaging over conventional methods are anticipated to boost the multiplex biomarker imaging market report over the forecast years. However, the high cost of the instruments, ethical issues of biomarker imaging techniques, and stringent regulatory policies are anticipated to impede the growth of market. Multiplex biomarker imaging is a technique carried to characterize and analyze the disease present in the body. Biomarkers are used in clinical studies to determine the diseases progress. Multiplex biomarkers have a major role in the medical industry and these are used in alone or combination to determine the characteristics and evaluate as an indicator of biological process. Multiplex biomarkers also help in the study of biological system by providing analysis to check the expression of various biomarkers. In August 2017, Quanterix launched high-sensitivity instrument Quanterix SR-Plex and assays for multiplex biomarker detection.

Multiplex Biomarker Imaging Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

–Latin America
Multiplex Biomarker Imaging Market Dynamics

Multiplex biomarker imaging market expected to exhibit significant growth due to successful determination and validation of clinical data for various diseases related to cancer cells and immune cells. Majority of the market players are actively involved in the development of newer products and techniques to determine the disease progress. For instance, in December 2015, PerkinElmer, Inc. launched Vectra 3 system used to determine the deeper level analysis of disease mechanisms related to newer cancer immunotherapy approaches. Moreover, in September 2017, Aushon BioSystems and ABL, Inc. announced the adoption of Cira platform for ultrasensitive and multiplex biomarker analysis.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Multiplex Biomarker Imaging Market Segmentation

product type
  • Instrument
  • Reagents and Kits
  • Software
imaging technique
  • Tissue Microarray (TMA)
  • Toponome Imaging System (TIS)
  • Fluorescent In The Situ Hybridization (FISH)
  • Immunofluorescence Assay (IF)
  • Immunohistochemistry Assay (IHC)
  • Oncology
  • Immunology
  • Drug Safety
  • Drug Discovery
end user
  • Biotechnology and Pharmaceutical Companies
  • Academic Research Institutes
  • Contract Research Organizations

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Bio-rad Laboratories Inc. (U.S.)
  • Abcam plc. (U.K.)
  • Perkin Elmer, Inc. (U.S.)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • Merck KGaA (Germany)
  • Aushon BioSystems Ltd. (U.S.)
  • ToposNomos Ltd (Germany)
  • Ventana Medical Systems, Inc. (U.S.)
  • US Biomax Inc. (U.S.)
  • Quanterix (U.S.)